A comprehensive view of Blood Disorders. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Consumer Wellness Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Pfizer gains FDA approval for its gene therapy Beqvez for hemophilia B treatment, pricing it at US$3.5M, matching the cost of the world's most expensive drug, Hemgenix; the therapy aims to provide long-term benefits and potentially reduce costs
Published: April 26, 2024 by FiercePharma
Pfizer gains FDA approval for BEQVEZ, a one-time dose treatment for adults with moderate to severe hemophilia B; the treatment is currently under review in Europe and was recently approved in Canada
Published: April 26, 2024 by Pfizer Inc.
BRISTOL MYERS SQUIBB CO - 10-Q - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Published: April 25, 2024 by SEC Edgar Filings
Sanofi's rilzabrutinib meets primary endpoint in Phase 3 LUNA 3 study for immune thrombocytopenia; potential for clinically beneficial treatment of several immune diseases underscored, with regulatory submissions in the US and EU expected by year-end
Published: April 23, 2024 by Sanofi SA
European Commission approves Jannsen's CARVYKTI ciltacabtagene autoleucel cilta-cel for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy; it is the first BCMA-targeted treatment approved by the EC
Published: April 22, 2024 by Janssen Pharmaceutical Companies

Ask us about our Consumer Wellness market view

Trending Chart

Interactive chart with headline count